Author: Johnson & Johnson

News

Johnson & Johnson’s Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm

June 1, 2026
Johnson & Johnson
No Comments

Patients were nine times more likely to have little to no cancer remaining in the prostate…